GlaxoSmithKline: Lymphoma trials
The registry lists 15 Lymphoma studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 1 9Phase 2 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompletedNCT03674567Phase 1/2Results posted
- PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)TerminatedNCT02378038Phase 2Results posted
- PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)CompletedNCT02226965Phase 2Results posted
- A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic MalignanciesCompletedNCT01943851Phase 2Results posted
- Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT01733238Phase 2Results posted
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's LymphomaCompletedNCT00989664Phase 2Results posted
- A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT02048488Phase 1/2
- A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)WithdrawnNCT01244009Phase 2
- A Study of PNT2258 in Patients With Advanced Solid TumorsCompletedNCT01191775Phase 1
- Dose-Escalation Study of GSK2126458CompletedNCT00972686Phase 1
- A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795CompletedNCT00920257Phase 1
- Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00742144Phase 1
- Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693TerminatedNCT00493818Phase 1
- Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or LymphomaCompletedNCT00406757Phase 1
- Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or LymphomasCompletedNCT00085904Phase 1